The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
British journal of haematology
follicular lymphoma; ibrutinib; rituximab
This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton's tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once-daily ibrutinib 560 mg continuously plus once-weekly rituximab 375 mg/m
Fowler, Nathan H; Nastoupil, Loretta; De Vos, Sven; Knapp, Mark; Flinn, Ian W; Chen, Robert; Advani, Ranjana H; Bhatia, Sumeet; Martin, Peter; Mena, Raul; Davis, Richard Eric; Neelapu, Sattva S; Eckert, Karl; Ping, Jerry; Co, Melannie; Beaupre, Darrin M; Neuenburg, Jutta K; and Palomba, M Lia, "The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma." (2020). Articles, Abstracts, and Reports. 2952.